Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Page 13 of 15
Feb 5, 2026PrimeGen’s decision to go public via a Special Purpose Acquisition Company (SPAC) represents an important step in the evolving regenerative medicine landscape. This strategic move not only provides capital for advancing a promising pre-clinical stem cell pipeline but also highlights growing investor interest in transformative cell therapies targeting unmet medical needs.
Feb 4, 2026The year 2021 marked an unprecedented wave of biotech initial public offerings, heavily influenced by pandemic-related funding surges. This article analyzes where these companies stand today, their challenges, and implications for future biotech investment landscapes.
Feb 3, 2026The biotech sector is encountering a notably active week for IPOs with four companies navigating toward public listings despite governmental operational interruptions. This development illustrates both market demand for innovative healthcare solutions and the strategic approaches companies adopt to overcome regulatory obstacles in pursuit of capital markets.
Feb 2, 2026The prominence of women’s health in the healthcare ecosystem has surged, propelled by specialized technologies and robust investment activity. This article delves into the factors underpinning this sector’s scalability and the regulatory frameworks shaping its development.
Feb 1, 2026This merger brings together two major players in the healthcare industry to offer integrated primary care, behavioral health, pharmacy services, and care navigation designed for large self-insured employers. It signals a shift toward more comprehensive, scalable employer health solutions.
Jan 31, 2026The health technology landscape entered 2026 with vigor, seen through four notable funding announcements that signal robust investor confidence. These funding rounds underpin developments in digital health, telemedicine, and biotechnology, marking an exciting chapter for healthcare innovation and investment.
Jan 29, 2026AstraZeneca continues to establish its footprint as a prolific investor in China’s biotech arena. This substantial capital infusion, following a recent $630 million commitment for full rights to AbelZeta’s cancer cell therapy, signals a robust strategic focus on advancing cell therapies and radiopharmaceutical technologies within the Chinese market.
Jan 29, 2026With growing awareness about the importance of lung health amid environmental challenges and respiratory concerns, Climatic's innovative inhalant product aims to establish a new category in preventive lung care. The company's recent funding underscores investor confidence in lung wellness solutions targeting proactive daily use.
Jan 27, 2026Digital health solutions continue to reshape healthcare delivery, demanding innovative contracting strategies. PHTI’s new playbook outlines how purchasers can effectively apply performance-based contracts to ensure measurable outcomes and accountability in digital health technologies.
Jan 26, 2026The biotech company Revolution Therapeutics currently stands at a crucial junction as multiple pharmaceutical companies potentially eye acquisitions. Merck's recent step back from pursuit places Revolution in a position to reassess its market worth amid growing investor speculation. This development sheds light on the dynamic nature of biopharmaceutical mergers and acquisitions in today's fast-evolving healthcare landscape.
Jan 25, 2026The recent significant fundraising by AnswersNow represents a pivotal development in the domain of autism care. With backing from prominent investors, their strategy to enhance therapy access could have far-reaching effects on service delivery models and patient outcomes for individuals with autism spectrum disorder.
Jan 23, 2026The significant capital infusion will fuel Corxel’s efforts to push CX11 through mid-stage development in the United States and prepare for pivotal Phase III clinical trials, underscoring investor confidence in oral GLP-1 therapies.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.